Literature DB >> 16312168

Effect of fluticasone propionate-salmeterol therapy on seasonal changes in airway responsiveness and exhaled nitric oxide levels in patients with pollen-induced asthma.

Luis Prieto1, Valentina Gutiérrez, Carmen Pérez-Francés, Carlos Badiola, Amparo Lanuza, Laura Bruno, Anna Ferrer.   

Abstract

BACKGROUND: There has been concern that in allergic asthmatic patients there might be an interactive effect on inflammation between regular salmeterol use and exposure to allergens, resulting in increased airway responsiveness.
OBJECTIVE: To determine the effects of salmeterol on allergen-induced changes in airway responsiveness and exhaled nitric oxide (ENO) levels in allergic asthmatic patients concomitantly taking inhaled corticosteroids.
METHODS: Forty-two asthmatic patients sensitized to pollen allergens were randomly allocated to treatment with fluticasone propionate-salmeterol (n=21) or fluticasone propionate alone (n=21). Spirometry, the methacholine provocation concentration causing a 20% decline in forced expiratory volume in 1 second (PC20), the adenosine 5'-monophosphate (AMP) PC20, and ENO levels were measured before and at the height of the pollen season after 6 weeks of treatment.
RESULTS: Changes in the methacholine PC20, the AMP PC20, and ENO levels were not significantly different between treatment groups. No significant changes in the AMP PC20 were observed among the fluticasone propionate-salmeterol and fluticasone propionate groups during natural pollen exposure. However, a significant increase in the methacholine PC20 was observed in the fluticasone propionate-salmeterol group (P = .03) and in the fluticasone propionate group (P = .04); ENO concentrations decreased significantly in both groups during natural allergen exposure (P = .009 and .005).
CONCLUSIONS: In patients with pollen-induced asthma, treatment with either fluticasone propionate or fluticasone propionate-salmeterol is associated with significant reductions in methacholine responsiveness and ENO concentrations, even during natural pollen exposure. Furthermore, at least in patients with mild asthma, natural allergen exposure and the regular use of fluticasone propionate-salmeterol are not associated with a greater increase in ENO levels and airway responsiveness than natural allergen exposure and fluticasone propionate use alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16312168     DOI: 10.1016/S1081-1206(10)61171-4

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  4 in total

1.  Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study.

Authors:  Luis Prieto; Ricardo Palacios; Dulce Aldana; Anna Ferrer; Carmen Perez-Frances; Victoria Lopez; Rocio Rojas
Journal:  Allergy Asthma Clin Immunol       Date:  2010-09-16       Impact factor: 3.406

Review 2.  Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.

Authors:  Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

Review 3.  Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children.

Authors:  Muireann Ni Chroinin; Toby J Lasserson; Ilana Greenstone; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

Review 4.  Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children.

Authors:  Bhupendrasinh F Chauhan; Caroline Chartrand; Muireann Ni Chroinin; Stephen J Milan; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2015-11-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.